XML 60 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration, License, Co-Promotion and Other Commercial Agreements - China, Hong Kong and Macau (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Aug. 31, 2014
Oct. 31, 2012
Mar. 31, 2017
Mar. 31, 2016
Collaboration, License and Co-Promotion Agreements        
Collaborative arrangements revenue     $ 51,877 $ 66,042
Linaclotide        
Collaboration, License and Co-Promotion Agreements        
Collaborative arrangements revenue     200  
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau        
Collaboration, License and Co-Promotion Agreements        
Prior notice period to terminate the agreement   180 days    
Up-front fee received   $ 25,000    
Additional budget for activities supporting the development of linaclotide $ 14,000      
Total amount of non-contingent arrangement consideration   34,000    
Amount of arrangement consideration for clinical trial material supply services and research, development and regulatory activities   $ 9,000    
Percentage of costs of clinical trial material supply services and research, development and regulatory activities allocated   55.00%    
Arrangement Consideration allocated to the License Deliverable   $ 29,700    
Arrangement Consideration allocated to the R&D Services   1,800    
Arrangement Consideration allocated to the JDC services   100    
Arrangement Consideration allocated to the clinical trial material supply services   300    
Arrangement Consideration allocated to Co-Promotion Deliverable   2,100    
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Linaclotide        
Collaboration, License and Co-Promotion Agreements        
Collaborative arrangements revenue     $ 208 $ 130
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Sales milestones        
Collaboration, License and Co-Promotion Agreements        
Milestone payment to be received by company upon milestone achievement   $ 125,000    
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Commercialization milestone        
Collaboration, License and Co-Promotion Agreements        
Percentage of net profit from commercialization   55.00%    
Percentage of net loss from commercialization   55.00%